United Therapeutics annual debt-to-ebitda ratio
2009
2010
2013
2014
2015
2021
2022
2023
2024
United Therapeutics Debt-to-EBITDA Ratio Growth & History (UTHR)
United Therapeutics's debt-to-ebitda ratio was 0.21 for fiscal 2024.
View full United Therapeutics company overviewUnited Therapeutics annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 0.21 | −0.36 | −63.39% |
| 2023 | 2023-12-31 | 0.57 | −0.21 | −27.14% |
| 2022 | 2022-12-31 | 0.78 | −0.54 | −41.24% |
| 2021 | 2021-12-31 | 1.32 | — | — |
| 2015 | 2015-12-31 | 0.01 | −0.21 | −96.67% |
| 2014 | 2014-12-31 | 0.22 | −0.45 | −66.79% |
| 2013 | 2013-12-31 | 0.67 | — | — |
| 2010 | 2010-12-31 | 1.25 | −4.68 | −78.97% |
| 2009 | 2009-12-31 | 5.93 | — | — |
United Therapeutics quarterly debt-to-ebitda ratio
Q4.10
Q1.11
Q2.11
Q3.11
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.22
Q4.24
Q1.25
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2025 | 2025-03-31 | 0.14 | — | — |
| Q4 2024 | 2024-12-31 | 0.21 | — | — |
| Q3 2022 | 2022-09-30 | 0.01 | — | — |
| Q2 2016 | 2016-06-30 | 0.00 | −0.10 | −99.23% |
| Q1 2016 | 2016-03-31 | 0.00 | −0.33 | −98.56% |
| Q4 2015 | 2015-12-31 | 0.01 | −0.21 | −96.67% |
| Q3 2015 | 2015-09-30 | 0.04 | −0.58 | −93.59% |
| Q2 2015 | 2015-06-30 | 0.10 | −0.35 | −78.43% |
| Q1 2015 | 2015-03-31 | 0.34 | −0.15 | −31.18% |
| Q4 2014 | 2014-12-31 | 0.22 | −0.45 | −66.79% |
| Q3 2014 | 2014-09-30 | 0.62 | 0.18 | +39.71% |
| Q2 2014 | 2014-06-30 | 0.44 | −0.02 | −3.70% |
| Q1 2014 | 2014-03-31 | 0.49 | — | — |
| Q4 2013 | 2013-12-31 | 0.67 | — | — |
| Q3 2013 | 2013-09-30 | 0.44 | — | — |
| Q2 2013 | 2013-06-30 | 0.46 | — | — |
| Q3 2011 | 2011-09-30 | 0.86 | — | — |
| Q2 2011 | 2011-06-30 | 0.98 | — | — |
| Q1 2011 | 2011-03-31 | 1.23 | — | — |
| Q4 2010 | 2010-12-31 | 1.25 | — | — |
United Therapeutics debt-to-ebitda ratio trends
Between the periods ended 2009-12-31 and 2024-12-31, United Therapeutics's debt-to-ebitda ratio decreased from 5.93 to 0.21, a change of −5.72. The latest reported quarter, Q1 2025, shows 0.14.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review United Therapeutics source filings ↗